Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Reishi owes an exceptional value in nutritional, cosmeceutical, and medical treatments; however, none of the studies has provided its future‐driven critical assessment. This study documents an up‐to‐date review (2015–2020, wherever applicable) and provide valuable insights (preclinical and clinical evidence‐based) with comprehensive and critical assessments. Various databases ‘Google scholar’, ‘Web of Science’, ‘ScienceDirect’, ‘PubMed’, ‘Springer Link’, books, theses, and library resources were used. The taxonomic chaos of G. lucidum and its related species was discussed in detail with solution‐oriented emphasis. Reishi contains polysaccharides (α/β‐D‐glucans), alkaloids, triterpenoids (ganoderic acids, ganoderenic acids, ganoderol, ganoderiol, lucidenic acids), sterols/ergosterol, proteins (LZ‐8, LZ‐9), nucleosides (adenosine, inosine, uridine), and nucleotides (guanine, adenine). Some active drugs are explored at an optimum level to make them potential drug candidates. The pharmacological potential was observed in diabetes, inflammation, epilepsy, neurodegeneration, cancer, anxiety, sedation, cardiac diseases, depression, hepatic diseases, and immune disorders; however, most of the studies are preclinical with a number of drawbacks. In particular, quality clinical data are intensely needed to support pharmacological activities for human use. The presence of numerous micro‐, macro, and trace elements imparts an essential nutritional and cosmeceutical value to Reishi, and various marketed products are available already, but the clinical studies regarding safety and efficacy, interactions with foods/drinks, chronic use, teratogenicity, mutagenicity, and genotoxicity are missing for Reishi. Reishi possesses many valuable pharmacological activities, and the number of patents and clinical trials is increasing for Reishi. Yet, a gap in research exists for Reishi, which is discussed in detail in the forthcoming sections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Believe it or not: how much can we rely on published data on potential drug targets?
Prinz, F., Schlange, T., & Asadullah, K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439-c1 · Cited by 1,888
Small studies: strengths and limitations
Hackshaw, A. (2008) · European Respiratory Journal · doi:10.1183/09031936.00136408 · Cited by 496 · cited 1×
“Yes, indeed, such kinds of studies (enrolling patients, reviewing patient records, performing biochemical analyses/asking subjects to complete study questionnaires) are help- ful, and data produced thereof may be utilised to design confirmatory studies on a large scale (Hackshaw, 2008).”
BackgroundSena, E. S., Currie, G. L., McCann, S. K., Macleod, M. R., & Howells, D. W. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.28 · Cited by 264
Kang, Q., Chen, S., Li, S., Wang, B., Liu, X., Hao, L., & Lu, J. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.215 · Cited by 150
Metadata
- Authors
- Ahmad, R., Riaz, M., Khan, A., Aljamea, A., Algheryafi, M., Sewaket, D., & Alqathama, A.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2021-08-19
- Volume
- 35
- Issue
- 11
- Pages
- 6030-6062
- ISSN
- 0951-418X (ISSN-L)
- 1099-1573
- OpenAlex
- W3195243445
- Cited by
- 181
- References
- 5
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. https://app.cochat.ai/papers/10.1002/ptr.7215
- The paper
- Ahmad, R., Riaz, M., Khan, A., Aljamea, A., Algheryafi, M., Sewaket, D., & Alqathama, A. (2021). Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties. Phytotherapy Research. https://doi.org/10.1002/ptr.7215
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.